BioXcel Therapeutics (BTAI) Total Liabilities (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Total Liabilities of $139.6 million for Q1 2026, up 8.41% year-over-year from $128.7 million in Q1 2025, and down 0.58% quarter-over-quarter from $140.4 million in Q4 2025.
BioXcel Therapeutics (BTAI) Total Liabilities (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Total Liabilities history runs 10 years deep, the most recent figure standing at $139.6 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 8.41% year-over-year to $139.6 million; the TTM figure through Mar 2026 stood at $139.6 million (up 8.41% YoY), while the FY2025 annual figure was $140.4 million, up 6.8% from the prior year.
- Total Liabilities for Q1 2026 stood at $139.6 million, down from $140.4 million in the prior quarter.
- The five-year high for Total Liabilities was $154.7 million in Q1 2024, with the low at $17.0 million in Q1 2022.
- The 5-year median for Total Liabilities is $133.5 million (2025), against an average of $124.5 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 646.91% in 2022, then fell 16.77% in 2025.
- BioXcel Therapeutics' Total Liabilities stood at $129.1 million in 2022, then rose by 0.88% to $130.2 million in 2023, then gained by 0.94% to $131.4 million in 2024, then rose by 6.8% to $140.4 million in 2025, then dropped by 0.58% to $139.6 million in 2026.
- Business Quant data shows BTAI's Total Liabilities at $139.6 million in Q1 2026, $140.4 million in Q4 2025, and $133.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.12 Bn |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | 144.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144.26 Mn |
| Mar 31, 2026 | 139.57 Mn |
| Dec 31, 2025 | 140.38 Mn |
| Sep 30, 2025 | 133.71 Mn |
| Jun 30, 2025 | 133.46 Mn |
| Mar 31, 2025 | 128.74 Mn |
| Dec 31, 2024 | 131.44 Mn |
| Sep 30, 2024 | 134.53 Mn |
| Jun 30, 2024 | 139.74 Mn |
| Mar 31, 2024 | 154.69 Mn |
| Dec 31, 2023 | 130.21 Mn |
| Sep 30, 2023 | 141.06 Mn |
| Jun 30, 2023 | 134.23 Mn |
| Mar 31, 2023 | 127.10 Mn |
| Dec 31, 2022 | 129.08 Mn |
| Sep 30, 2022 | 117.83 Mn |
| Jun 30, 2022 | 83.97 Mn |
| Mar 31, 2022 | 17.03 Mn |
| Dec 31, 2021 | 17.77 Mn |
| Sep 30, 2021 | 15.78 Mn |